Jinru Shia

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

  Clinical Cancer Research · 2026-06-26

• Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer

  Clinical Cancer Research · 2026-04-21

• Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer

  The American Journal of Surgical Pathology · 2026-04-21

• Abstract B034: Genetic and non-genetic mechanisms of resistance to KRAS inhibition in CRC

  Cancer Research · 2026-03-05

• Risk of Metachronous Colorectal Cancer After Segmental or Extended Resection in Patients with Lynch Syndrome

  Journal of the American College of Surgeons · 2026-03-03

• Quo Vadis colorectal intramucosal adenocarcinoma?

  Journal of Clinical Pathology · 2026-02-18

• ASO Visual Abstract: The Effect of Pathological Response to Preoperative Therapy on Margin Status and Outcomes After Resection of Colorectal Liver Metastases

  Annals of Surgical Oncology · 2026-02-05

• A neural network model delivers a highly prognostic protein signature in cancer stem cells that identifies relapse in stage III colorectal cancer patients

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-13

• The Effect of Pathologic Response to Preoperative Therapy on Margin Status and Outcomes After Resection of Colorectal Liver Metastases

  Annals of Surgical Oncology · 2026-01-11

• Changing landscape of multidisciplinary management in locally advanced rectal cancer (2015-2023).

  Journal of Clinical Oncology · 2026-01-10

• Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Risk of Residual Cancer After Immediate Surgery or Nonoperative Management After Malignant Colorectal Polypectomy With High-Risk Features

  JCO oncology advances. · 2025-12-01